title: Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function.
abstract: OBJECTIVE
  Proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta have been implicated in the pathogenesis of myocardial dysfunction in ischemia-reperfusion injury, sepsis, chronic heart failure, viral myocarditis, and cardiac allograft rejection. Although circulating TNF-alpha and IL-1beta are both often elevated in septic shock, it remains unknown whether TNF-alpha or IL-1beta are the factors induced during sepsis that directly depress human myocardial function, and if so, whether the combination synergistically depresses myocardial function. Furthermore, the mechanism(s) by which these cytokines induce human myocardial depression remain unknown. We hypothesized the following: a) TNF-alpha and IL-1beta directly depress human myocardial function; b) together, TNF-alpha and IL-1beta act synergistically to depress human myocardial function; and c) inhibition of ceramidase or nitric oxide synthase attenuates myocardial depression induced by TNF-alpha or IL-1beta by limiting proximal cytokine signaling or production of myocardial nitric oxide (NO).
  
  
  METHODS
  Prospective, randomized, controlled study.
  
  
  METHODS
  Experimental laboratory in a university hospital.
  
  
  METHODS
  Freshly obtained human myocardial trabeculae.
  
  
  METHODS
  Human atrial trabeculae were obtained at the time of cardiac surgery, suspended in organ baths, and field simulated at 1 Hz, and the developed force was recorded. After a 90-min equilibration, TNF-alpha (1.25, 12.5, 125, or 250 pg/mL for 20 mins), IL-1beta (6.25, 12.5, 50, or 200 pg/mL for 20 mins), or TNF-alpha (1.25 pg/mL) plus IL-1beta (6.25 pg/mL) were added to the bath, and function was measured for the subsequent 100 mins after the 20-min exposure. To assess the roles of the sphingomyelin and NO pathways in TNF-alpha and IL-1beta cross-signaling, the ceramidase inhibitor N-oleoyl ethanolamine (1 microM) or the NO synthase inhibitor N(G)-monomethyl-L-arginine (10 microM) was added before TNF-alpha (125 pg/mL) or IL-1beta (50 pg/mL).
  
  
  RESULTS
  TNF-alpha and IL-1beta each depressed human myocardial function in a dose-dependent fashion (maximally depressing to 16.2 + 1.9% baseline developed force for TNF-alpha and 25.7 + 6.3% baseline developed force for IL-1beta), affecting systolic relatively more than diastolic performance (each p < .05). However, when combined, TNF-alpha and IL-1beta at concentrations that did not individually result in depression (p > .05 vs. control) resulted in contractile depression (p < .05 vs. control). Inhibition of myocardial sphingosine or NO release abolished the myocardial depressive effects of either TNF-alpha or IL-1beta.
  
  
  CONCLUSIONS
  TNF-alpha and IL-1beta separately and synergistically depress human myocardial function. Sphingosine likely participates in the TNF-alpha and IL-1beta signal leading to human myocardial functional depression. Therapeutic strategies to reduce production or signaling of either TNF-alpha or IL-1beta may limit myocardial dysfunction in sepsis.
authors.affiliation: Department of Surgery, University of Colorado Health Sciences Center, Denver 80262, USA.
authors.forename: B S
authors.initials: BS
authors.lastname: Cain
authors.forename: D R
authors.initials: DR
authors.lastname: Meldrum
authors.forename: C A
authors.initials: CA
authors.lastname: Dinarello
authors.forename: X
authors.initials: X
authors.lastname: Meng
authors.forename: K S
authors.initials: KS
authors.lastname: Joo
authors.forename: A
authors.initials: A
authors.lastname: Banerjee
authors.forename: A H
authors.initials: AH
authors.lastname: Harken
mesh_terms: D000581:Amidohydrolases / Q000037:antagonists & inhibitors; D009202:Cardiomyopathies / Q000378:metabolism* / Q000473:pathology*; D055572:Ceramidases; D003327:Coronary Disease / Q000503:physiopathology; D006325:Heart Atria / Q000473:pathology; D006801:Humans; D007375:Interleukin-1 / Q000493:pharmacokinetics / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D011446:Prospective Studies; D018805:Sepsis / Q000503:physiopathology*; D013110:Sphingosine / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000493:pharmacokinetics / Q000502:physiology*
chemical_list: D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D019001:Nitric Oxide Synthase; D000581:Amidohydrolases; D055572:Ceramidases; D013110:Sphingosine